Glen Santangelo, an analyst from Jefferies, reiterated the Buy rating on ANI Pharmaceuticals (ANIP – Research Report). The associated price target remains the same with $80.00.
Glen Santangelo has given his Buy rating due to a combination of factors that reflect strong performance and growth potential for ANI Pharmaceuticals. The company has demonstrated significant volume growth in its generics segment, with a notable increase in year-over-year volumes driven by recent product launches. This momentum is expected to continue, providing opportunities for revenue and EBITDA growth that exceed current market expectations.
Additionally, the established brands segment is contributing positively to the company’s financial performance, with high-margin products supporting EBITDA growth. While the rare disease segment is experiencing some seasonal softness, it is still showing robust growth, and the overall valuation of the company suggests that it is undervalued compared to its peers. These elements combined make ANI Pharmaceuticals an attractive investment opportunity, justifying the Buy rating from Glen Santangelo.
In another report released on March 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $94.00 price target.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANIP in relation to earlier this year.